What Mass Spectrometry Establishes That HPLC Cannot
Purity and identity are different questions requiring different instruments. Why a chromatogram alone cannot tell you which peptide is in the vial, and what a mass spectrum on a COA should actually show.
A Certificate of Analysis showing 99.4% purity and nothing else tells you the vial contains 99.4% of one thing.
It does not tell you what that thing is.
This is not a pedantic distinction. Purity and identity are genuinely separate questions, they are answered by different instruments, and the gap between them is where substitution happens in the research peptide market.
What chromatography can and cannot do
HPLC separates a mixture by how strongly each component interacts with a stationary phase. Components emerge at different times, a detector records them, and the result is a trace of peaks against retention time.
That gives you two pieces of information:
- Relative quantity — from peak area. This is what the purity percentage is.
- Retention time — a weak identity indicator.
Retention time is weak for a specific reason: it is a property of the method, not of the molecule. Change the column, the gradient, the temperature or the mobile phase and it changes. Two laboratories running the same peptide will get different retention times.
More importantly, many different molecules share a retention time on any given method. A peptide and its single-residue deletion sequence often co-elute or nearly co-elute. Two members of the same analogue family frequently do. Retention time can support an identification against a reference standard run on the same system that day; on its own it establishes very little.
What mass spectrometry adds
Mass spectrometry measures a property of the molecule itself: its mass.
The sample is ionised — for peptides, almost always by electrospray — and the instrument measures mass-to-charge ratios of the resulting ions. Software converts that to molecular mass, which is compared against the theoretical mass calculated from the intended sequence.
That comparison is the identity test. Every amino acid has a known residue mass, so a sequence has an exactly calculable mass. Material that matches within instrument tolerance is the compound it claims to be. Material that does not is something else, and the size of the discrepancy usually says what.
| Discrepancy | Likely cause |
|---|---|
| −57 Da | Missing glycine |
| −71 Da | Missing alanine |
| −113/−114 Da | Missing leucine/isoleucine, or asparagine |
| −186 Da | Missing tryptophan |
| +16 Da | Oxidation (commonly methionine) |
| +1 Da | Deamidation (asparagine → aspartate) |
| −2 Da | Disulfide bond formed |
| ~2× mass | Dimer |
Note how many of these are small. A +16 Da oxidation or a +1 Da deamidation does not move a peak far on a chromatogram, and may not move it at all. On a mass spectrum they are unambiguous.
Where this matters most
Analogue families. Compounds in the incretin class — semaglutide, tirzepatide, retatrutide — share substantial structural similarity, similar lipidation, similar chromatographic behaviour and very different prices. Substituting one for another is invisible to a purity measurement and immediately obvious on a mass spectrum, because the masses differ by hundreds of daltons.
Fragment ambiguity. "TB-500" refers in practice both to full-length thymosin β4 (~4,963 Da) and to the Ac-LKKTETQ fragment (~889 Da). That is a factor-of-five difference in mass and a much larger difference in synthesis cost. Any real MS result resolves it instantly; no purity figure can.
Form ambiguity. "CJC-1295" refers to both the DAC (~3,647 Da) and non-DAC (~3,368 Da) forms, which behave differently in every design where receptor occupancy duration is a variable.
Deletion sequences. The impurity class chromatography handles worst, and mass spectrometry handles best.
Reading a mass spectrometry result
A certificate should give you both numbers:
- Theoretical mass — calculated from the sequence. Arithmetic, not a result.
- Observed mass — what the instrument measured. The actual result.
Showing both lets a reader check the comparison. Showing only "MS: confirmed" or only one figure asks the reader to take the comparison on trust, which defeats the purpose of publishing it.
Monoisotopic versus average mass
Two different theoretical masses can be calculated for the same molecule, and mixing them up produces an apparent discrepancy where there is none.
Monoisotopic mass uses the lightest isotope of each element. Average mass uses the isotope-weighted average. For a small peptide the difference is under a dalton; for a 5,000 Da peptide it can be two or three daltons.
A certificate should say which convention it is using. When observed and theoretical differ by a small amount on a large peptide, this is the first thing to check.
Multiply charged ions
Electrospray adds protons — often several. A 4,963 Da peptide is commonly observed not at 4,963 but as a series: the 3+ ion at m/z ≈ 1,655, the 4+ at ≈ 1,242, the 5+ at ≈ 993. The instrument measures mass-to-charge, and deconvolution software reconstructs the molecular mass from the series.
This is worth knowing because a mass spectrum of a large peptide showing a single clean peak at exactly the molecular weight is not what real electrospray data looks like. It is what someone unfamiliar with the technique would draw.
What mass spectrometry does not establish
Being clear about the limits matters as much as the capabilities.
It does not distinguish stereoisomers. D- and L-amino acids have identical masses. Ipamorelin contains two D-residues, and a synthesis that incorporated the L-form at either position would produce a diastereomer with an identical mass spectrum. Only chromatography — with a method that resolves them — can see this.
It does not distinguish leucine from isoleucine. Identical formulas, identical masses.
It does not quantify. Ionisation efficiency varies between species, so peak intensity in a mass spectrum is not proportional to abundance. Quantitation is chromatography's job.
Standard MS does not confirm sequence order. A peptide and a scrambled version of the same residues have the same mass. Establishing order requires tandem MS (MS/MS), where the molecule is fragmented and the fragment masses read back. This is not part of a routine release package, and a certificate claiming "sequence confirmed by MS" from a single-stage measurement is overstating what was done.
The two methods together
Neither instrument answers the whole question.
HPLC establishes how much of the material is the main component, and — with a chromatogram you can actually see — what the impurity profile looks like.
Mass spectrometry establishes that the main component is the intended molecule.
A certificate with both has addressed purity and identity. A certificate with purity alone has established that a vial contains 99% of something, and left the more consequential question open.
Related: how to read a peptide COA and reading an HPLC chromatogram.